COVID-19 Vaccination Schedule for Most People
(People who are NOT Moderately or Severely Immunocompromised)

**People ages 6 months through 4 years**

**Moderna**
- DOSE 1 (primary) In 4-8 weeks
- DOSE 2 (primary)

**Pfizer-BioNTech**
- DOSE 1 (primary) In 3-8 weeks
- DOSE 2 (primary) In at least 8 weeks
- DOSE 3 (primary)

**People ages 5 through 11 years**

**Moderna**
- DOSE 1 (primary) In 4-8 weeks
- DOSE 2 (primary)

**Pfizer-BioNTech**
- DOSE 1 (primary) In 3-8 weeks
- DOSE 2 (primary) In at least 5 months
- DOSE 3 (Monovalent Booster)

**People ages 12 years and older**

**Moderna, Novavax, or Pfizer-BioNTech**
- DOSE 1 (primary) or in 4-8 weeks (Moderna) In 3-8 weeks (Novavax, Pfizer)
- DOSE 2 (primary) In at least 2 months
- DOSE 3* (Bivalent booster)

**People ages 18 years and older who previously received Janssen primary series dose†**

- DOSE 1 (primary) In at least 2 months
- DOSE 2* (Bivalent booster)

---

**Note:** This schedule does not include clinical details necessary for administering COVID-19 vaccines. For clinical details, see the resources at the end of this document.

* The bivalent booster dose is administered at least 2 months after completion of the primary series. For people who previously received a monovalent booster dose(s), the bivalent booster dose is administered at least 2 months after the last monovalent booster dose.

† Janssen COVID-19 Vaccine should only be used in certain limited situations. See: [https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a)

For more specific clinical guidance, see:
- [Pre-exposure prophylaxis](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a)
- [Interim COVID-19 Immunization Schedule](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a)
- [Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States](https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us-appendix.html#appendix-a)
COVID-19 Vaccination Schedule for People Who Are Moderately or Severely Immunocompromised

People ages 6 months through 4 years

**Moderna**

- **DOSE 1** (primary) - In 4 weeks
- **DOSE 2** (primary) - In at least 4 weeks
- **DOSE 3** (primary) - In 4 weeks

**Pfizer-BioNTech**

- **DOSE 1** (primary) - In 3 weeks
- **DOSE 2** (primary) - In at least 8 weeks
- **DOSE 3** (primary) - In at least 3 months

**People ages 5 years through 11 years**

**Moderna**

- **DOSE 1** (primary) - In 4 weeks
- **DOSE 2** (primary) - In at least 4 weeks
- **DOSE 3** (primary) - In 4 weeks

**Pfizer-BioNTech**

- **DOSE 1** (primary) - In 3 weeks
- **DOSE 2** (primary) - In at least 4 weeks
- **DOSE 3** (primary) - In at least 3 months
- **DOSE 4** (Monovalent Booster)

For more specific clinical guidance, see:

- Pre-exposure prophylaxis
- Interim COVID-19 Immunization Schedule
- Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States
COVID-19 Vaccination Schedule for People Who Are Moderately or Severely Immunocompromised

People ages 12 years and older

**Modern or Pfizer-BioNTech**

1. **DOSE 1** (primary)
   - In 3-8 weeks
   - or in 4 weeks (Moderna)
2. **DOSE 2** (primary)
   - In at least 4 weeks
3. **DOSE 3** (primary)
   - In at least 2 months
4. **DOSE 4** (Bivalent booster)

**Novavax**

1. **DOSE 1** (primary)
2. **DOSE 2** (primary)
   - In at least 4 weeks
   - In at least 2 months
3. **DOSE 3** (primary)
   - In at least 2 months
4. **DOSE 4** (Bivalent booster)

**People ages 18 years and older who previously received Janssen primary series dose†**

1. **DOSE 1** (primary)
2. **DOSE 2** (Adll mRNA dose)
3. **DOSE 3** (Bivalent booster)

Monoclonal antibodies (EVUSHELD™) for COVID-19 pre-exposure prophylaxis

**People ages 12 years and older (must weigh at least 40kg)**

1. Any dose (primary or booster)
2. **EVUSHELD™** dose every 6 months
3. No minimum interval from EVUSHELD™ to COVID-19 vaccine
4. Any subsequent COVID-19 vaccine dose

**Note:** This schedule does not include clinical details necessary for administering COVID-19 vaccines. For clinical details, see the resources at the end of this document.

- The bivalent booster dose is administered at least 2 months after completion of the primary series. For people who previously received a monovalent booster dose(s), the bivalent booster dose is administered at least 2 months after the last monovalent booster dose.
- Janssen COVID-19 Vaccine should only be used in certain limited situations. See: [https://www.cdc.gov/vaccines/](https://www.cdc.gov/vaccines)